The breast feeding mother and xenon anaesthesia: four case reports. Breast feeding and xenon anaesthesia by Stuttmann, Ralph et al.
RESEARCH ARTICLE Open Access
The breast feeding mother and xenon
anaesthesia: four case reports. Breast feeding and
xenon anaesthesia
Ralph Stuttmann
1*, Claudia Schäfer
1, Peter Hilbert
1, Markus R Meyer
2, Hans H Maurer
2
Abstract
Background: Four nursing mothers consented to anaesthesia for urgent surgery only on condition that their
ability to breast feed would not be impaired.
Methods: Following induction of general anaesthesia with propofol and remifentanil, 65-69% xenon supplemented
with remifentanil was used as an inhalational anaesthetic for maintenance.
Results: After finishing surgery the women could be extubated between 2:52 and 7:22 minutes. The women were
fully alert just minutes after extubation and spent about 45 minutes in the recovery room before discharge to a
regular ward. They resumed regular breast feeding some time later. The propofol concentration in the blood was
measured after 0, 30, 90, and 300 minutes and in the milk after 90 and 300 minutes. Just 90 minutes after
extubation, the concentration of propofol in the milk was limited (> 3 mg/l) so that pharmacological effects on the
babies were excluded after oral intake. Also, no traces of xenon gas were found in the maternal milk at any time.
After propofol induction and maintenance of anaesthesia with xenon in combination with a water-soluble short-
acting drug like remifentanil, the concentration of propofol in maternal milk is low (> 3 mg/l 90 min after
anesthesia) and harmless after oral intake.
Conclusions: These results, as well as the rapid elimination and absence of metabolism of xenon, are of great
interest to nursing mothers. General anaesthesia with propofol for induction only, combined with remifentanil and
xenon for maintenance, has not yet been described in breast feeding mothers.
Background
Surgery and general anaesthesia during pregnancy and
lactation are limited in terms of the techniques and
drugs that can safely be used. Traces of anaesthetics
have little or no effect on older infants, but may cause
problems in neonates or pre-term babies predisposed to
apnoea [1]. In such cases, breast feeding must be sus-
pended for 12-24 hours. Many mothers attach great
importance to exclusive breast feeding with no supple-
mentary bottle feed. In urgent surgery, when the opera-
tion cannot be properly scheduled and only general
anaesthesia is possible or acceptable to breast feeding
mothers, a technique of anaesthesia is desirable which
allows the babies to be safely breast fed shortly after
surgery. A general recommendation is an interruption of
breast feeding for 24 h following anaesthesia but without
clear evidence to the author’sk n o w l e d g e .T h i si sd i s -
agreeable to mother and baby. Once xenon has been
granted marketing approval in 14 countries in Europe, it
may become an interesting and new technique for gen-
eral anaesthesia with a special indication for mothers
breast feeding their babies. The aim was to prove this
indication in four case reports with control of the blood
and milk concentrations of anaesthetic agents.
Methods
We enrolled four mothers of ASA classification I who
attached great importance to nursing and refused regio-
nal anaesthesia in urgent surgery. We therefore sug-
gested inhalational anaesthesia with xenon. Each patient
consented to this approach, and cases three and four
also agreed to blood and milk samples being taken.
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Case #1
A 31-year-old mother had suffered a recurrent slipped
disc. She was exclusively breast feeding her 5-month-old
infant until just before surgery.
Case #2
A 30-year-old tertipara had suffered a flake fracture of
the talus requiring urgent surgery. She was still mostly
breast feeding her 5-month-old infant, as well as giving
some additional food. The infant was last nursed about
2.5 h before induction of anaesthesia.
Case #3
A 34-year-old secundipara had developed a ganglion on
the hand during pregnancy and was scheduled for sur-
gery after delivery. The infant, who was mainly breast
fed, was last nursed by the patient just before attending
the hospital for ambulatory surgery.
Case #4
A 30-year-old mother suffered a fractured fibula requir-
ing urgent osteosynthesis. Her 3-month-old baby was
exclusively breast fed, the last time shortly prior to
surgery.
The direct perioperative anaesthesiological approach was
identical for the four women. After an infusion of balanced
Ringer’s acetate solution, routine monitoring devices were
set up. A Narcotrend® monitor (MT MonitorTechnik
GmbH und Co. KG, 24576 Bad Bramstedt, Maienbass 27,
Germany) validated for xenon anaesthesia by the author
was used to monitor the anaesthetic depth by single-lead
EEG [2]. Anaesthesia was induced and controlled by the
target controlled infusion technique (TCI) using the Base
Primea® unit (Fresenius Kabi GmbH, Bad Homburg, Ger-
many). Propofol was used for induction of anaesthesia
based on the dosing model of Schnider [3] and remifenta-
nil was used for analgesia based on the dosing model of
Minto [4]. The anaesthesia ventilator was the Dräger Phy-
sioflex closed system. Induction of anaesthesia ensued
with a calculated effect concentration of 6.5 μg.ml
-1 for
propofol and 4.5 ng.ml
-1 for remifentanil according to the
model of Schnider and Minto [3,4]. Following preoxygena-
tion and ventilation with oxygen, Esmeron® (rocuronium
bromide) 0.5 mg/kg was injected for neuromuscular block-
ing to facilitate intubation. Monitoring of the neuromus-
cular transmission is routine clinical practice. Thereafter,
the Physioflex was used for controlled ventilation with an
equal setting (tidal volume 8 ml per kg bodyweight and
frequency 9 breaths per minute) on the ventilator in all
cases. The breathing system was repeatedly flushed with
oxygen. Once the endexpiratory oxygen concentration
reached about 99% some minutes later, the inspiratory
oxygen concentration was reduced to 24%, and xenon
insufflation was started by repeated flushing. Propofol
infusion was stopped as xenon insufflation was started.
The target xenon concentration was between 69% and
65%, and the depth of anaesthesia ranged from sleep stage
E0 to E1 on the Narcotrend® witch means sufficient depth
of anesthesia [5].
In two patients samples of blood (0, 30, 90, and 300
minutes after anaesthesia) and milk (90 and 300 minutes
after anaesthesia) were taken to measure the propofol
and xenon concentration. EDTA blood samples were
taken, centrifuged, and the plasma stored at - 54°C after
shock freezing.
Sample Preparation and Quantification
After addition of 50 mL butyl acetate, plasma samples
(200 mL) and maternal milk samples were extracted for
2 min on a rotary shaker. After centrifugal phase separa-
tion (1 min, 10,000 3 g, ambient temperature), the upper
layer (organic) was transferred to autosampler vials, and
2 mL injected into the gas chromatography (GC)-mass
spectrometry (MS) system.
The samples were analysed using a Hewlett Packard
(Agilent, Waldbronn, Germany) HP 6890 Series GC sys-
tem combined with an HP 5973 series mass selective
detector, an HP 6890 Series injector, and an HP Chem
Station G1701AA version A.03.00. The GC conditions
were as follows: splitless injection mode; column, HP-1
capillary (Agilent), 12 m × 0.2 mm internal diameter,
cross-linked methyl silicone, 330 nm film thickness;
injection port temperature, 280°C; carrier gas, helium;
flow rate 0.6 mL/min; column temperature, initially 100°
C for 2 min, increased to 310°C at 40°/min, 310°C for
2.5 min. The MS conditions were as follows: transfer
line heater, 280°C; ion source temperature, 230°C; elec-
tron mode; ionisation energy, 70 eV; selected ion moni-
toring (SIM) with the following programme: solvent
delay, 3.00 minutes; m/z 117, 163 (target ion), and 178
for propofol. The electron multiplier voltage offset was
set to 50 V from 3.00 to 6.00 min.
Full calibration quantification of propofol was carried
out by comparison of its peak area in the sample with
that of calibration curves, in which the peak areas of
spiked calibrators had been plotted against their concen-
trations (0.1, 0.5, 1.0, 2.5, 5.0, 7.5, 10.0 mg/L).
The maternal milk samples for measuring xenon con-
centration were injected directly into special glass tubes
for gas chromatography and stored at 4°C until the time
of estimation.
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ensued with the help of a commercial ICP-MS (induc-
tively coupled plasma mass spectrometer) in a time
resolved measurement mode on several xenon isotope
masses. The sample introduction method for xenon
measurement was developed by Carsten Pilger (Air
Liquide medical GmbH).
Results
The four operations were uneventful. Table 1 gives infor-
mation about patient data, time of operation, time of
extubation, xenon supply and xenon consumption. Upon
completion of all measures, the remifentanil dose was
reduced to an effective dose of 1.5 ng.ml
-1,a n do n c et h e
calculated plasma concentration had decreased to below
1.5 ng.ml
-1, the ventilatory system was flushed with oxy-
gen, thus simultaneously stopping the supply of xenon.
Once the xenon concentration was less than about 20%
and all patients opened their eyes and could follow com-
mands, their tracheas were extubated. The patients were
then transferred to the recovery room and monitored for
about 45 minutes before being returned to the ward fully
alert with permission to eat and drink. None of the
women experienced nausea or vomiting at any time.
In case #1, the mother resumed nursing at 12:00 noon
(2 hours and 50 min after anesthesia). In case #2, the
infant was bottle fed at midday, and regular nursing was
resumed in the evening (4 hours and 40 min after
anesthesia). The third baby was breast fed 5 hours after
the end of anaesthesia, and the fourth baby after 90
minutes. During the first nursing session all babies were
observed very carefully for dizziness and drowsiness, but
no such signs were seen. The subsequent period at
home was completely uneventful, both for the babies
and their mothers.
Table 2 gives information about the concentration of
propofol in the blood and breast milk as well as xenon
in the breast milk. The blood concentration of propofol
is low just 30 minutes after extubation. After 90 and
300 minutes, propofol was measured in the milk and
calculated for a volume of 150 ml (Table 3). No traces
of xenon could be detected.
Discussion
Xenon was discovered in 1898 by Ramsay and Travers.
It is the only noble gas with anaesthetic properties
under normobaric conditions [6]. Cullen successfully
performed general anaesthesia with xenon for the first
time in 1951[7]. Xenon comes very close to being the
ideal anaesthetic [8-12]. Its unique properties include a
rapid onset and offset of action [13] and a recovery
index with good arousal quality [14].
Breast feeding is known to have significant benefits in
terms of infant development. The World Health Organi-
sation (WHO) recommends exclusive breast feeding for
6 months and partial continuation into the second year
of life [15]. How safe is breast milk for the infant, how-
ever, if the mother has taken medication? Unfortunately,
recommendations tend to be based on case reports, the-
oretical risks or case studies [16].
The breast milk accumulation in 24 hours of most
drugs is rarely greater than 1-2% of the original dose
[17]. Drugs with high lipid solubility like propofol are
found at higher concentrations in breast milk than in
plasma dependent on the time and amount of milk pro-
duction during propofol administration. This could be
confirmed when determining the levels of propofol in
t h eb l o o da n dm a t e r n a lm i l k9 0a n d3 0 0m i n u t e sp o s t
extubation. Water-soluble drugs with low molecular
weight (< 200) are excreted in the breast milk unim-
peded, resulting in identical milk and plasma concentra-
tions. As a result of the difference between plasma pH
(7.4) and milk pH (6.5-7.09), weak acids are excreted in
smaller quantities in milk, whilst weak bases are
excreted in higher concentrations. High protein binding
as is the case with remifentanil (70%) is associated with
low milk concentrations, since only the free fraction of a
drug can enter the breast milk. Remifentanil is metabo-
lised within minutes by nonspecific plasma esterases and
Table 1 Details of patient age, OP time, xenon duration, extubation time and xenon consumption
Patient Age [years] Weight (kg) OP time [min] Xenon time [min] Extubation time [min] Xenon consumption [l]
1 31 78 40 60 2:52 15.00
2 30 64 45 70 7:22 15.33
3 33 60 35 57 6:30 10.00
4 30 58 35 59 4:51 8.28
Table 2 Concentration of propofol and xenon in the
blood and maternal milk after 0, 30, 90 and 300 minutes
post extubation
Time (t) after extubation [min]
Sample Case 0 30 90 300
Propofol [mg/l] Blood #3 0.47 0.47 0.21 0.12
#4 0.48 0.45 0.16 0.11
Maternal milk #3 0.13
#4 2.78 0.84
Xenon Maternal milk #3 0 0
#4 0 0
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kely. A high degree of ionisation as with Esmeron
results in an exceedingly low drug concentration in the
milk [17-19].
Xenon, a noble gas, is absorbed or exhaled via the
lungs. It does not form any compounds in the body and
is not metabolised. The partition coefficients increase
from xenon to nitrous oxide, sevoflurane and isoflurane.
The blood/gas partition coefficient is the main determi-
nant of the rate of onset and offset of action of an inha-
lational anaesthetic. The lower the blood/gas partition
coefficient, the faster these processes. The oil/gas parti-
tion coefficient or the lipid solubility of an inhalational
anaesthetic is a measure of its potency: a high lipid solu-
bility means high potency but also a longer emergence
time [6,20]. The low lipid solubility of xenon explains its
high minimal alveolar concentration (MAC) as well as
its short recovery times.
Xenon has excellent physicochemical properties,
explaining its anaesthetic effect under normobaric condi-
tions. The MAC of xenon ranges from 51% to 69%
[21-23]. The oil/water partition coefficient of xenon is
around 20. Based on the physical properties of xenon and
a breast-milk fat concentration of approximately 51%,
dissolution of xenon in human milk cannot be ruled out
completely, but would theoretically be expected to be
lower than that of sevoflurane or isoflurane, respectively.
Since an accumulation process in breast milk is not pos-
sible based on diffusion gradients and because the resi-
dual concentration of xenon is exhaled from the mother’s
body in a matter of minutes, considerations suggest that
xenon is no longer detectable in the milk a few minutes
after emergence. This suggestion is consistent with the
concentration of xenon we measured in the breast milk
(see Table 2). Furthermore it can be assumed that during
the suction process traces of xenon diffuse from the milk
into the air within seconds, so that the question of oral
bioavailability does not arise.
The unique benefits of inhalational anaesthesia with
xenon in nursing mothers include rapid elimination in a
matter of minutes, the absence of metabolism of this
noble gas and analgetic properties.
Accounts in the literature on the anaesthetic approach
to nursing mothers are sparse [19,24,25]; guidelines do
not reflect this setting, and textbooks recommend inter-
ruption of breast feeding for 24 h. Nor do the propofol
and remifentanil SPCs (Summary of Product Character-
istics) comment on usage during lactation.
Remifentanil, co-administered with xenon to ensure
analgesia, is rapidly metabolised postoperatively and has
a plasma half-life of 3-10 minutes. At a calculated effect
concentration of less than 1.5 ng/ml read from the Base
Primea controller at extubation, it is therefore safe to
assume that this opioid is no longer active. No data is
available on the excretion of remifentanil in breast milk
(information provided by the manufacturer).
Propofol was used only for induction. Nitsun and col-
leagues found that the breast-milk drug concentration
was 0.015% of the original dose over a 24 h measuring
period [26]. This represents the upper limit based on
the assumption that the infant ingests the total milk
volume produced during a 24 h period and that propo-
fol has 100% oral bioavailability. In light of the two
cases in which propofol was measured in the breast
milk, this would imply that a maximum of 52.5 μg/24 h
could be absorbed in case 3 and 66.45 μg/24 h in case
4. Assuming that a baby drinks about 150 ml per breast
feed, this amount - when converted in line with the
concentrations in the maternal milk after 90 and 300
minutes - is equivalent to the doses given in Table 3. In
case 4 we could detect a clear deviation from the claim
made by Nitsun et al after just 90 and 300 minutes,
with 0.09% and 0.028% of the measured concentration
in the breast milk related to the initial dose. Hence the
findings published by Nitsun et al do not apply to our
patients and require further investigation in a larger
population. Nevertheless, it can be presumed that orally,
the baby ingests an extremely low concentration of pro-
pofol. Taken also into account the very low oral bioa-
vailability babies will be exposed to a negligible quantity
of propofol during breast feeding.
Conclusion
Xenon anaesthesia is an alternative method for nursing
mothers, enabling breast feeding to be resumed immedi-
ately after surgery without harming the baby. This is
also the case in surgery lasting several hours, since pro-
pofol is given only for induction. When given inhala-
tionally for anaesthetic maintenance, xenon does not
accumulate and is exhaled within a few minutes irre-
spective of the duration of inhalation. The measure-
ments clearly demonstrate that, 90 minutes after
extubation, neither amounts of lipid-soluble propofol
nor xenon can be detected in milk. The unique benefits
of inhalational anaesthesia with xenon in nursing
mothers include rapid elimination in a matter of min-
utes, the absence of metabolism of this noble gas and
analgetic properties. Xenon anaesthesia combined with
Table 3 Initial doses of propofol [mg] and related
concentrations [mg], as well as percentages in the
maternal milk after 90 and 300 minutes related to
150 ml
Case ∑ Propofol IV [mg] mg/150 ml maternal milk
90 min 300 min
#3 350 0.0195 (0.006%)
#4 443 0.417 (0.09%) 0.126 (0.028%)
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thetic technique recommendable for breast feeding
mothers on paediatric grounds.
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